BerGenBio ASA
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRRGF research report →
Companywww.bergenbio.com
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19.
- CEO
- Oystein Soug
- IPO
- 2018
- Employees
- 13
- HQ
- Bergen, NO
Price Chart
Valuation
- Market Cap
- $9.49B
- P/E
- -17.00
- P/S
- 38.78
- P/B
- 27.30
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.06%
- Op Margin
- -2133.21%
- Net Margin
- -1990.43%
- ROE
- -113.42%
- ROIC
- -172.08%
Growth & Income
- Revenue
- $23.02M · 2615.09%
- Net Income
- $-154,982,477 · -11.27%
- EPS
- $-125.02 · -973.13%
- Op Income
- $-141,645,007
- FCF YoY
- 17.49%
Performance & Tape
- 52W High
- $97.09
- 52W Low
- $0.03
- 50D MA
- $97.09
- 200D MA
- $97.09
- Beta
- 1.31
- Avg Volume
- 3.95K
Get TickerSpark's AI analysis on BRRGF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BRRGF Coverage
We haven't published any research on BRRGF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BRRGF Report →